Summer 2027

Legal Intern

FMC

FMC

5,001-10,000 employees

Develops pesticides and sustainable agricultural solutions

No salary listed

Philadelphia, PA, USA

Hybrid

Hybrid position at FMC headquarters in Philadelphia.

Bachelor's, Master's

Category
Legal (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to FMC

See people who can refer or advise you

Requirements
  • Pursuing a bachelor's degree or graduate degree.
  • Demonstrated knowledge of basic law principles.
  • Ability to perform administrative work with a high degree of proficiency and autonomy.
  • Strong organizational skills with a focus on details and accuracy.
  • Must have completed the first year of undergraduate study.
  • Proficiency with Microsoft Office products, including Excel, PowerPoint, Teams, and Word.
Responsibilities
  • Assist with drafting, reviewing, and managing contracts and other legal documents to ensure compliance with company policies and applicable laws.
  • Support business transactions and strategic initiatives by gathering, reviewing, and analyzing legal and corporate information.
  • Maintain and organize legal records, contracts, and regulatory documents in accordance with FMC's governance requirements.
  • Assist with compliance activities, legal research, audits, and regulatory requirements to support FMC's ethics and compliance programs.
  • Participate in legal and business meetings, document key takeaways, and support communication.

FMC develops and supplies crop protection products, including herbicides, insecticides, and fungicides, plus formulations and technologies that help protect crops from pests and diseases. Its products work by using chemical active ingredients and tailored formulations that control pests while aiming to minimize environmental impact; the company emphasizes science-driven solutions to improve efficacy and safety in farming. Compared with competitors, FMC leverages a long history (over a century) and a clear focus on sustainable technologies that protect both crops and the environment, with ongoing discovery of new actives and innovative formulations. The company’s goal is to help feed the world’s growing population by delivering effective crop protection that is better for the planet.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Philadelphia, Pennsylvania

Founded

1883

Get referred to FMC

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Isoflex EU approval on April 6, 2026 opens launches across 55 million hectares.
  • FMC expects roughly $1 billion proceeds from Tessenderlo, India, Corteva, and leaseback deals.
  • Q2 2026 cash from operations hit $363 million, aided by the $200 million Corteva payment.

What critics are saying

  • Q2 2026 revenue fell 17%; 2026 EBITDA guidance now $620 million-$680 million.
  • Net debt was $4.3 billion in Q2 2026, forcing covenants and collateral pledges.
  • India sale, bond issuance, and strategic review signal a balance-sheet rescue, not growth.

What makes FMC unique

  • FMC’s 2026 pipeline includes Isoflex EU approval and rimisoxafen’s first dual-mode classification.
  • Tessenderlo’s $400 million investment validates FMC’s asset base and deleveraging plan.
  • New active ingredients reached about $200 million sales in 2025, up 54% year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Family Planning Benefits

Mental Health Support

Company News

Yahoo Finance
Jul 29th, 2026
FMC Corporation Q2 2026: $153M adjusted EBITDA beats guidance despite 17% revenue decline

FMC Corporation reported second quarter 2026 revenue of $867 million, down 17% year-over-year, with adjusted EBITDA of $153 million exceeding guidance. Excluding India, revenue fell 20% to $841 million, with organic revenue declining 22%. The company posted a GAAP net loss of $187 million, or $1.49 per diluted share. Adjusted earnings per share reached $0.26, down 62% from the prior year. Cash from operations rose significantly to $363 million, up $297 million year-over-year. FMC lowered its full-year outlook due to challenging macroeconomic conditions. The company now expects revenue excluding India of $3.50 billion to $3.70 billion and adjusted EBITDA between $620 million and $680 million. Free cash flow guidance increased to $75 million to $225 million, including a $200 million upfront licensing payment for rimisoxafen.

AInvest Fintech Inc.
Jul 1st, 2026
Tessenderlo to invest $400M for 20% stake in FMC at $13.30 per share

Tessenderlo Group has agreed to invest $400 million in FMC Corporation for a 20% stake at $13.30 per share, valuing the agricultural sciences company at approximately $2 billion. The transaction concludes FMC's strategic review initiated in February 2026 and supports its $1 billion debt reduction target. The Belgian industrial group described the investment as part of its strategy to acquire cornerstone minority stakes in high-quality agricultural companies. FMC said the agreement aligns with its operational plans, including advancing its R&D pipeline and commercialising new innovations. The deal follows recent FMC initiatives including a $1.2 billion bond offering, the $252 million sale of its India business, and a $200 million prepayment from Corteva. The transaction requires regulatory approvals and customary closing conditions.

MarketScreener
Jul 1st, 2026
FMC secures $400M from Tessenderlo Group to hit $1B debt paydown target

FMC Corporation, a global agricultural sciences company, has reached a definitive agreement with Belgian industrial group Tessenderlo Group for a $400 million minority equity investment at $13.30 per share. Upon completion, Tessenderlo Group will own approximately 20% of FMC's outstanding shares. The transaction concludes FMC's strategic options review announced in February 2026. FMC will use the proceeds to pay down debt, reaching its approximately $1 billion debt paydown target. Recent actions include raising $1.2 billion in secured bonds, selling its India commercial business for $252 million, and securing a $200 million prepayment from a Corteva agreement. The deal is subject to regulatory approvals. BofA Securities and Goldman Sachs advised FMC, whilst Stibbe and Sullivan & Cromwell advised Tessenderlo Group.

Simply Wall St
May 21st, 2026
FMC raises $750M in secured notes to ease leverage as dividend slashed 86%

FMC Corporation has raised $750 million through senior secured notes due 2031, issued under Regulation S and Rule 144A with guarantees. The fixed-income offering aims to strengthen the company's financial position and provide flexibility for operations, debt management and potential growth initiatives. The financing comes alongside a sharp dividend cut announced in April 2026, from $0.58 to $0.08 per share, signalling management's focus on cash preservation and balance sheet repair. FMC faces elevated leverage and weak interest coverage, making debt management the key near-term catalyst. Whilst the bond issue may ease short-term liquidity pressure, the company's investment narrative still depends on restoring profitability and cash generation in its crop protection business. Some analysts project FMC could reach $4.5 billion in revenue and $429 million in earnings.

Yahoo Finance
May 13th, 2026
FMC reaffirms $3.6B-$3.8B 2026 sales guidance despite $281M Q1 loss and India exit

FMC Corporation reported first-quarter 2026 sales of $758.6 million and a net loss of $281.3 million, whilst maintaining its full-year 2026 sales guidance of $3.6 billion to $3.8 billion. The company is navigating a planned mid-single-digit price decline and the removal of India sales from its portfolio. Despite the quarterly loss, management's decision to reaffirm annual guidance signals confidence in volume growth and new product launches to offset pricing pressure and the India exit. The company faces ongoing challenges from elevated leverage and weak interest coverage. The narrative projects FMC could reach $4 billion in revenue and $286.1 million in earnings by 2029, with a fair value estimate of $17.53 representing 33% upside. The stock has fallen 11.6% following the announcement.